A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
A phase 2 trial of SHR-A1904 for Injection in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer is a phase 2 interventional study registered as NCT07450976 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 151 participants planned, started 2026-03-25 and due to reach its primary completion in 2030-12. Interventions recorded: SHR-A1904 for Injection.
Similar pages
not linked directly; found by shared links- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Jiangsu Hengrui Pharmaceuticals, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialHetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.